"Sanofi's decision to retain 50% of the capital is a guarantee that these activities will be anchored in France in the long term," the statement added. The emergence of regulatory concerns over ...

Sanofi SAN-0.92%decrease; red down pointing triangle is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company ...

The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than cutting costs. Chris Hughes is a Bloomberg Opinion columnist covering ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

PARIS, Oct 20 (Reuters) - Sanofi (SASY.PA), opens new tab on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...

PAI Partners has submitted an improved offer for Sanofi’s consumer health business, according to people familiar with the matter, an unexpected twist in one of the biggest deals in Europe this year.

Sanofi expects a low single-digit decline in flu shot sales due to the soft vaccination rate. Sanofi reaffirms that Dupixent will deliver around 13 billion euros in 2024 sales. The company ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Sanofi has struck a deal in the hotly competitive radiopharmaceuticals sector, buying a $300mn stake in a ...

Sanofi pitched today’s announcement in the context of its move last month to pay Orano Med and its partner RadioMedix 100 million euros upfront and commit up to 220 million euros in sales ...

Sanofi SA (NASDAQ:SNY) and private equity Clayton Dubilier & Rice (CD&R) have finally entered into exclusive negotiations to potentially sell and purchase a 50% controlling stake in Opella, Sanofi ...